Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Sangeetha VenugopalMahran ShoukierMarina KonoplevaCourtney D DinardoFarhad RavandiNicholas James ShortMichael AndreeffGautam BorthakurNaval G DaverNaveen PemmarajuKoiji SasakiGuillermo Montalban BravoKayleigh R MarxSherry PierceUday R PopatElizabeth J ShpallRashmi Kanagal-ShamanaGuillermo Garcia ManeroHagop M KantarjianTapan Mahendra KadiaPublished in: Cancer (2021)
The addition of VEN to standard treatment regimens did not improve outcomes in younger or older patients who had TP53mut AML. These data highlight the need for novel therapies beyond VEN to improve the outcome of patients with TP53mut AML.